SCHEMBL4412669

SCHEMBL4412669

Nc1ccc2c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)[nH]c2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 1/20 0.70
FBP1 P09467 1/20 0.39
MAPT P10636 3/20 0.38
CA12 O43570 2/20 0.35
CA9 Q16790 2/20 0.35
TP53 P04637 3/20 0.35
KMT2A Q03164 5/20 0.35
MEN1 O00255 4/20 0.35
LMNA P02545 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
HTT P42858 1/20 0.35
RECQL P46063 1/20 0.35
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
GAA P10253 3/20 0.33
ERCC1 P07992 1/20 0.33
FEN1 P39748 1/20 0.33
ERCC4 Q92889 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9922489 0.91 P2RY12 (0.72) P2RY12FBP1MAPTCA12CA9
SCHEMBL9922487 0.90 P2RY12 (0.78) P2RY12FBP1MAPTTP53KMT2A
SCHEMBL6017209 0.88 P2RY12 (0.54) P2RY12MAPTCA12CA9TP53
SCHEMBL9922813 0.87 P2RY12 (0.69) P2RY12FBP1MAPTCA12CA9
SCHEMBL9922447 0.87 P2RY12 (0.69) P2RY12MAPTCA12CA9TP53
SCHEMBL9922301 0.87 P2RY12 (0.67) P2RY12FBP1MAPTKMT2AMEN1
SCHEMBL9922560 0.87 P2RY12 (0.69) P2RY12FBP1MAPTTP53KMT2A
SCHEMBL9922564 0.87 P2RY12 (0.69) P2RY12FBP1MAPTTP53KMT2A
SCHEMBL9922558 0.86 P2RY12 (0.66) P2RY12FBP1MAPTTP53KMT2A
SCHEMBL13635110 0.86 P2RY12 (0.66) P2RY12FBP1MAPTTP53KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1863798-B 2, 4-dioxo-3-quinazolinyl arylsulfonyl urea PORTOLA PHARM INC 2011-08-31 CN disclosed
EP-1668002-B1 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS PORTOLA PHARM INC (US) 2009-11-11 EP disclosed
EP-1668002-B1 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS PORTOLA PHARM INC (US) 2009-11-11 EP disclosed
EP-1668002-A4 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS PORTOLA PHARM INC (US) 2006-12-20 EP disclosed
CN-1863798-A 2, 4-dioxo-3-quinazolinyl arylsulfonyl urea PORTOLA PHARM INC (US) 2006-11-15 CN disclosed
US-7109332-B2 2,4-dioxo-3-quinazolinylaryl sulfonylureas PORTOLA PHARMACEUTICALS, INC. (US) 2006-09-19 US disclosed
EP-1668002-A2 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS Portola Pharmaceuticals, Inc. (US) 2006-06-14 EP disclosed
US-20050107357-A1 2,4-dioxo-3-quinazolinylaryl sulfonylureas PORTOLA PHARMACEUTICALS, INC. (US) 2005-05-19 US disclosed
WO-2005032488-A2 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS PORTOLA PHARMACEUTICALS, INC. (US) 2005-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107357-A1 2,4-dioxo-3-quinazolinylaryl sulfonylureas PFKP, DPP3, P2RY13 P2RY12 21/4885FBP1 2377/4885MAPT 4788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.